BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102

BioCorRx (OTCQB: BICX) a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it has submitted a grant application to the National Institutes of Health (NIH) to fund the development and study plans for BICX102, the Company’s sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.

As quoted in the press release:

This specific grant opportunity, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3), was created as a result of the current opioid epidemic.

Brady Granier, President, CEO and Director, stated, “The NIH provides support for the research and development of new treatments that can help address the current epidemic of opioid use disorder, which is estimated to affect over 2 million Americans.  We are seeking funding from the NIH that could potentially cover the entire cost of the BICX102 development plan. We believe that this new grant opportunity is well suited for our product, as BICX102 addresses an unmet need in the treatment of opioid use disorder of an FDA approved, single administration, multi-month opioid antagonist treatment. While waiting for the outcome of this very comprehensive grant submission, we have already started procuring equipment and supplies needed for the manufacturing portion of the development plan.”

Click here to read the full press release.